Wistrom J, Norrby SR, Myhre EB. Frequency of antibioticassociated diarrhoea in 2462 antibiotictreated hospitalized patients: a prospective study. J Antimicrob Chemother, 2001, 47: 4350.

Bartlett JG. Antibioticassociated diarrhea. N Engl J Med, 2002, 346(5): 334339.

LaRosa M, Bottaro G, Gulino N. Prevention of antibioticassociated diarrhea with Lactobacillus sporogens and fructooligosaccharides in children: a multicentric doubleblind vs. placebo study. Minerva Pediatr, 2003, 55: 447452.

Turck D, Bernet JP, Marx J et al. Incidence and risk factors of oral antibioticassociated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr, 2003, 37: 2226.

McFarland LV. Probiotics and Diarrhea. Ann Nutr Metab, 2010, 57(1): 1011.

Закордонец Л.В., Крамарев С.А., Береговая Т.В., Толстанова А.Н., Довбинчук Т.В. Антибиотикассоциированная диарея: механизмы развития и возможности коррекции. Здоровье ребенка, 2013, 7: 69-73.

Vonberg RP, Reichardt C, Behnke M et al. Cost of nosocomial Clostridium difficileassociated diarrhea. J Hosp Infect, 2008, 70: 1520.

Hu Y et al. Exploring on the Status, Reasons and Countermeasures of Antibiotics Abuse. Chinese Journal of Social Medicine, 2013: 128-130.

McFarland LV. Epidemiology, risk factors and treatments for antibioticassociated diarrhea. Dig Dis., 1998, 16: 292307.

Lusk RH, Fekety FR, Silva JJ, Bodendorfer T, Devine BJ, Kawanishi H, Korff L, Nakauchi D, Rogers S, Siskin SB. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis, 1977, 135: 111119.

Плотникова Е.Ю., Захарова Ю.В. Роль пробиотиков в профилактике и лечении антибиотикассоциированной диареи. Доказательная гастроэнтерология, 2013, 4(2): 51-57.

Шевяков М.А. Антибиотик-ассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия, 2004, 10(49): 26-29.

Плотникова Е.Ю., Захарова Ю.В. Место пробиотиков в профилактике и лечении антибиотик-ассоциированной диареи. Терапевтический архив, 2015, 5(85): 127-131.

Modi N, Wilcox MH. Evidence of antibiotic induced Clostridium perfringens diarrhoea. J Clin Pathol, 2001, 54: 748–751.

Vaishnavi C, Kaur S, Singh K. Clostridium perfringens type A & antibiotic associated diarrhoea. Indian J Med Res, 2005, 122: 52–56.

Gravet A, Rondeau M, Harf-Monteil C, Grunenberger F, Monteil H, Scheftel JM, Prevost G. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD. J Clin Microbiol, 1999, 37: 4012–4019.

Beaugerie L, Metz M, Barbut F, Bellaiche G, Bouhnik Y, Raskine L, Nicolas JC, Chatelet FP, Lehn N, Petit JC. Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis. Clin Gastroenterol Hepatol, 2003, 1: 370–376.

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threatreport-2013. Accessed 29 Mar 2016.http://www.cdc.gov/drugresistance/threatreport-2013

Kim SW, Peck KR, Jung SI, Kim YS, Kim SM, Lee NY, Song JH. Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea. J Korean Med Sci, 2001, 16: 742-744.

Levine J, Dykoski RK, Janoff EN. Candidaassociated diarrhea: a syndrome in search of credibility. Clin Infect Dis, 1995, 21: 881-886.

Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect, 2001, 7: 405–10.

McFarland LV, Goh S. Preventing Pediatric Antibiotic-Associated Diarrhea and Clostridium difficile Infections with Probiotics: a meta-analysis. World J Meta-analysis, 2013, 1: 102-120.

Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis, 2015, 13: 128-134.

O’Connor JR, Johnson S & Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology, 2009, 136: 1913-1924.

Cohen SH et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection control and hospital epidemiology, 2010, 31: 431-455.

Kuijper EJ et al. Update of Clostridium difficileassociated disease due to PCR ribotype 027 in Europe. Euro surveillance: bulletin Europeen sur les maladies transmissibles. European communicable disease bulletin, 2007, 12: E1-2.

McDonald LC et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infection control and hospital epidemiology, 2007, 286: 140-145.

Collins DA, Riley TV. Routine detection of Clostridium difficile in Western Australia. Anaerobe, 2016, 37: 34-37.

Baldoni D, Gutierrez M, Timmer W. Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. The Journal of antimicrobial chemotherapy, 2014, 69: 06-714.

McDonald LC et al. An epidemic, toxin gene-variant strain of Clostridium difficile. The New England journal of medicine, 2005, 353: 2433-2441.

McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nature clinical practice. Gastroenterology & hepatology, 2008, 5: 40-48.

Warny M et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 2005, 366: 1079-1084.

Rea MC., et al. Effect of broadand narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(l): 4639–4644.

Magill SS et al. Multistate point-prevalence survey of health care-associated infections. The New England journal of medicine, 2014, 370: 1198–1208.

Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol, 2013, 108(4): 478-498.

Bagdasarian N, Rao K, Malani PN Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA, 2015, 313(4): 398-408.

McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibioticassociated diarrhea and Clostridium difficile infections. World J Gastroenterol, 2016 Mar 21, 22(11): 3078-3104.

Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol, 2011, 9: 1044-9.

Cremonini F, Di Caro S, Nista EC, et al. Metaanalysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther, 2002, 16: 1461-7.

McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology, 2006, 101: 812-22.

Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56: 772-81.

Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 2012, 35(12): 1355-1369.

Lau SM Christine, Ronald S. Chamberlain Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. International Journal of General Medicine, 2016, 22(9): 27-37.

Jafarnejad S, Shab-Bidar S, Speakman JR., Parastui K, Daneshi-Maskooni M, Djafarian K. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18–64 Years) but Not the Elderly (>65 Years). A Meta-Analysis. Nutrition in Clinical Practice, 2015, 31(4): 502-513.

Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 2015 Dec 22, 12: CD004827.

Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA, 2012 May 9, 307(18): 1959-69.

Vaughan RB. The romantic rationalist: a study of Elie Metchnikoff. Med Hist, 1965, 9: 201-215.

Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol, 2010 Sep, 3(5): 307-319.

FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Expert. Consultation. Report, 2001: 1-34.

Chatterjee S, Kar P, Das T, Ray et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India, 2013, 61: 708-12.

Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatmen. Scand J Infect Dis, 1991, 23: 247.

de Vrese M. Effects of probiotic bacteria on gastrointestinal symptoms, Helicobacter pylori activity and antibiotics-induced diarrhea. Gastroenterology, 2003, 124: A560.

de Vrese M, Kristen H, Rautenberg P et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res, 2011 Nov, 78(4): 396-403.

Sheu BS, Wu JJ, Lo CY et al. Impact of supplement with Lactobacillusand Bifidobacteriumcontaining yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2002 Sep, 16(9): 1669-75.